EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023–2024

Mateus Trinconi Cunha iD, Neil Wallace iD, Sandro Porceddu iD, Renata Ferrarotto iD

Cancer · 2025

DOI: 10.1002/cncr.35920 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Mateus Trinconi Cunha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Skin Neoplasms, Carcinoma, Squamous Cell, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies against PD‐1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsCarcinoma, Squamous CellImmunotherapyImmune Checkpoint InhibitorsHumansAntibodies, Monoclonal, HumanizedProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

PD‐1 inhibitors (PD1i)cutaneous squamous cell carcinomaimmune checkpoint inhibitors (ICI)immunosuppressionneoadjuvant

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptorcemiplimabpembrolizumabPDCD1 protein, human

Autor:innen und Institutionen

  • Division of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Mateus Trinconi Cunha, Neil Wallace, Sandro Porceddu, Renata Ferrarotto

Zitieren

APA

Trinconi Cunha, M., Wallace, N., Porceddu, S., & Ferrarotto, R. (2025). Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023–2024. Cancer. https://doi.org/10.1002/cncr.35920

Vancouver

Trinconi Cunha M, Wallace N, Porceddu S, Ferrarotto R. Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023–2024. Cancer. 2025. doi:10.1002/cncr.35920

BibTeX
@article{TrinconiCunha2025,
  author = {Trinconi Cunha, Mateus and Wallace, Neil and Porceddu, Sandro and Ferrarotto, Renata},
  title = {Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023–2024},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35920}
}
Kostenlos starten →